The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

James Cassidy

Cancer Research UK




Name/email consistency: high



  • Cancer Research UK, Glasgow, UK. 2010
  • Glasgow University, Garscube Estate, Switchback Rd, Glasgow, Scotland. 2008
  • Centre for Oncology and Applied Pharmacology, University of Glasgow, Glasgow G12 0YN, UK. 2008
  • CRC Department of Oncology, University of Glasgow, Garscube Estate, Bearsden, United Kingdom. 2004 - 2007
  • Beatson Oncology Centre, Glasgow, United Kingdom. 2005
  • Centre for Oncology and Applied Pharmacology, Cancer Research UK Beatson Laboratories, Division of Cancer Sciences and Molecular Pathology, University of Glasgow, UK. 2004
  • Department of Medicine and Therapeutics, University of Aberdeen, UK. 2002


  1. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. Cassidy, J., Saltz, L.B., Giantonio, B.J., Kabbinavar, F.F., Hurwitz, H.I., Rohr, U.P. J. Cancer Res. Clin. Oncol. (2010) [Pubmed]
  2. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. Cassidy, J., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.S., Rivera, F., Couture, F., Sirzén, F., Saltz, L. J. Clin. Oncol. (2008) [Pubmed]
  3. Cetuximab for the treatment of patients with colorectal cancer. Cassidy, J. Nature Clinical Practice. Oncology (2008) [Pubmed]
  4. Which first-line treatment is superior in advanced colorectal cancer: XELOX or pviFOX?. Cassidy, J. Nature Clinical Practice. Oncology (2007) [Pubmed]
  5. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Cassidy, J., Douillard, J.Y., Twelves, C., McKendrick, J.J., Scheithauer, W., Bustová, I., Johnston, P.G., Lesniewski-Kmak, K., Jelic, S., Fountzilas, G., Coxon, F., Díaz-Rubio, E., Maughan, T.S., Malzyner, A., Bertetto, O., Beham, A., Figer, A., Dufour, P., Patel, K.K., Cowell, W., Garrison, L.P. Br. J. Cancer (2006) [Pubmed]
  6. Benefits and drawbacks of the use of oral fluoropyrimidines as single-agent therapy in advanced colorectal cancer. Cassidy, J. Clin. Colorectal. Cancer (2005) [Pubmed]
  7. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. Cassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., Debraud, F., Figer, A., Grossmann, J., Sawada, N., Schöffski, P., Sobrero, A., Van Cutsem, E., Díaz-Rubio, E. J. Clin. Oncol. (2004) [Pubmed]
  8. Tumour-targeted drug and gene delivery: principles and concepts. Cassidy, J., Schätzlein, A.G. Expert. Rev. Mol. Med (2004) [Pubmed]
  9. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Cassidy, J., Twelves, C., Van Cutsem, E., Hoff, P., Bajetta, E., Boyer, M., Bugat, R., Burger, U., Garin, A., Graeven, U., McKendric, J., Maroun, J., Marshall, J., Osterwalder, B., Pérez-Manga, G., Rosso, R., Rougier, P., Schilsky, R.L. Ann. Oncol. (2002) [Pubmed]
WikiGenes - Universities